Surgical technique remains the most important factor associated with recovery of urinary continence after radical prostatectomy

Share :
Published: 16 Mar 2023
Views: 675
Rating:
Save
Dr Rafael Sanchez-Salas - McGill University Health Center, Montreal, Canada

Dr Rafael Sanchez-Salas speaks to ecancer about his talk at EAU 2023. His talk was on the IMPROVE trial and how surgical technique remains the most important factor associated with recovery of urinary continence after radical prostatectomy.

He suggests that professionals need to be highly trained in surgery for better patient outcomes. Neurovascular bundle preservation via surgery was the only factor found to be associated with recovery of urinary continence in the IMPROVE trial.

Dr Sanchez-Salas discusses how the results from this trial are game changing from a clinical perspective.
 

We are going to participate at the Game Changer session with a trial that was performed in Paris in France when I was working there. The name of the trial is IMPROVE and it’s a trial that is assessing continence after radical prostatectomy, actually robotic radical prostatectomy. 

The IMPROVE trial is quite important because it proves that the surgical technique and surgeon is the most important factor to recover continence after the procedure. There are several options of recovery measures that you can deploy but beyond those, including pelvic muscle floor training or pharmacologic options like duloxetine or solifenacin, at the end of the analysis with the nodal vascular bundle dissection related complete to surgical technique came up as the only factor really associated with continence recovery. 

How can the study results impact clinical practice?

At the end of the day it becomes simple. You need to improve your technique; you need to be well trained in robotic radical prostatectomy because that’s what we analysed. We did robotic radical prostatectomy, but the training, the exposure, through videos, through courses is essential because the more refined your technique is, the better your outcomes will be, especially the functional outcomes. We are talking about a similar situation to Formula 1, for instance: you can have the best car ever but if you are not a good driver you will never get on the podium.

I really want to thank you for giving me the opportunity to share the improved results and I hope the community, the urological community, assume how important surgical technique is for our patients. 


 

Related Videos

Breast and emerging indications for IORT

Dr David Martinez Perez - AUNA, Lima, Peru
Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023

The pros and cons of breast IORT and ultra hypofractionation (FR)

Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France
The pros and cons of breast IORT and ultra hypofractionation (FR) ( Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France )
4 Apr 2023

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )
18 Feb 2023

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023